LDL and HDL lipoprotein subfractions in multiple sclerosis patients with decreased insulin sensitivity

Open access


Objectives. Increased metabolic and cardiovascular morbidity has been reported in multiple sclerosis (MS) patients. Previously, we have found decreased insulin sensitivity and hyperinsulinemia in a group of newly diagnosed MS patients. We hypothesize that these features may be associated with an altered lipid profile and low, intermediate, or high density lipoprotein (LDL, IDL, HDL) subclasses accelerating atherosclerosis and thus contributing to the cardiovascular risk increase in these patients.

Subjects and methods. In a group of 19 newly diagnosed untreated MS patients with previously found hyperinsulinemia and insulin resistance and a matched group of 19 healthy controls, the lipoprotein subclasses profile was determined. Polyacrylamide gel electrophoresis was used to separate and measure the LDL (large LDL and small dense LDL), HDL (large, intermediate and small), and IDL (A, B and C) subclasses with the Lipoprint© System (Quantimetrix Corporation, Redondo Beach, CA, USA).

Results. No difference was found either in the conventional lipid or lipoprotein subclasses profile between the MS patients and healthy controls. We found an inverse association between the level of IDL-B with fasting insulin (r=–0.504, p=0.032), the insulin resistance estimated by homeo-static model assessment – insulin resistance (HOMA-IR) (r=–0.498, p=0.035), insulin response expressed as area under the curve (AUC; r=–0.519, p=0.027), and area above the baseline (AAB; r=–0.476, p=0.045) and positive association with insulin sensitivity estimated by insulin sensitivity index (ISI) Matsuda (r=0.470, 0.048) in MS patients, but not in healthy controls suggesting the first signs in lipoprotein subclasses profile change.

Conclusions. Our data indicate that changes in lipoprotein profile and subclasses are preceded by insulin resistance and hyperinsulinemia in patients with newly diagnosed MS.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Asztalos BF Cupples LA Demissie S Horvath KV Cox CE Batista MC Schaefer EJ. High-density lipoprotein sub-population profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24 2181–2187 2004.

  • Boyer JF Gourraud PA Cantagrel A Davignon JL Constantin A. Traditional cardiovascular risk factors in rheumatoid arthritis: A meta-analysis. Joint Bone Spine 78 179–183 2011.

  • Cederholm J Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 10 167–175 1990.

  • Feingold KR Grunfeld C. Introduction to Lipids and Lipoproteins. In: De Groot LJ Chrousos G Dungan K Feingold KR Grossman A Hershman JM Koch C Korbonits M McLachlan R New M Purnell J Rebar R Singer F Vinik A editors. Endotext [Internet]. South Dartmouth (MA): MDText.com Inc.; 2000 2018.

  • Fellows K Uher T Browne RW Weinstock-Guttman B Horakova D Posova H Vaneckova M Seidl Z Krasensky J Tyblova M Havrdova E Zivadinov R Ramanathan M. Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. J Lipid Res 56 2010–2018 2015.

  • Garvey WT Kwon S Zheng D Shaughnessy S Wallace P Hutto A Pugh K Jenkins AJ Klein RL Liao Y. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 453–462 2003.

  • Giubilei F Antonini G Di Legge S Sormani MP Pantano P Antonini R Sepe-Monti M Caramia F Pozzilli C. Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis. Acta Neurol Scand 106 109–112 2002.

  • Guerrero-Garcia JJ Carrera-Quintanar L Lopez-Roa RI Marquez-Aguirre AL Rojas-Mayorquin AE Ortuno-Sahagun D. Multiple Sclerosis and Obesity: Possible Roles of Adipokines. Mediators Inflamm 2016: Article ID: 4036232 2016.

  • Haffner SM American Diabetes Association. Management of Dyslipidemia in Adults With Diabetes. Diabetes Care 26 s83–s86 2003.

  • Ito K Yoshida H Yanai H Kurosawa H Sato R Manita D Hirowatari Y Tada N. Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. Int J Cardiol 168 3853–3858 2013.

  • Jorissen W Wouters E Bogie JF Vanmierlo T Noben JP Sviridov D Hellings N Somers V Valcke R Vanwijmeersch B Stinissen P Mulder MT Remaley AT Hendriks JJ. Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL. Sci Rep 7 43410 2017.

  • Jorissen W Vanmierlo T Wens I Somers V Van Wijmeersch B Bogie JF Remaley AT Eijnde BO Hendriks JJA. Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients. Int J Mol Sci 19 E193 2018.

  • Joshi PH Khokhar AA Massaro JM Lirette ST Griswold ME Martin SS Blaha MJ Kulkarni KR Correa A D’Agostino RB Sr Jones SR Toth PP; Lipoprotein Investigators Collaborative (LIC) Study Group. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Off-spring Cohort Studies. J Am Heart Assoc 5 e002765 2016.

  • Kassi E Pervanidou P Kaltsas G Chrousos G. Metabolic syndrome; definitions and controversies. BMC Med 9 48 2011.

  • Krauss RM PaulT.Williams PT Brensike J Detre KM Lindgren FT Kelsey SF Vranizan K Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. The Lancet 330 62–66 1987.

  • Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27 1496–1504 2004.

  • Lee JE Min SH Lee DH Oh TJ Kim KM Moon JH Choi SH Park KS Jang HC Lim S. Comprehensive assessment of lipoprotein subfraction profiles according to glucose metabolism status and association with insulin resistance in subjects with early-stage impaired glucose metabolism. Int J Cardiol 225 327–331 2016.

  • Mandoj C Renna R Plantone D Sperduti I Cigliana G Conti L Koudriavtseva T. Anti-annexin antibodies cholesterol levels and disability in multiple sclerosis. Neurosci Lett 606 156–160 2015.

  • Martin SS Faridi KF Joshi PH Blaha MJ Kulkarni KR Khokhar AA Maddox TM Havranek EP Toth PP Tang F Spertus JA Jones SR. Remnant Lipoprotein Cholesterol and Mortality After Acute Myocardial Infarction: Further Evidence for a Hypercholesterolemia Paradox From the TRIUMPH Registry. Clin Cardiol 38 660–667 2015.

  • Matsuda M DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 1462–1470 1999.

  • Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 412–419 1985.

  • Nakamura T Obata JE Hirano M Kitta Y Fujioka D Saito Y Kawabata K Watanabe K Watanabe Y Mishina H Kugiyama K. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 218 163–167 2011.

  • Penesova A Vlcek M Imrich R Vernerova L Marko A Meskova M Grunnerova L Turcani P Jezova D Kollar B. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis 30 895–901 2015.

  • Sicras-Mainar A Ruiz-Beato E Navarro-Artieda R Maurino J. Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia Spain. BMC Neurol 17 134 2017.

  • Srisawasdi P Vanavanan S Rochanawutanon M Kruthkul K Kotani K Kroll MH. Small-dense LDL/large-buoyant LDL ratio associates with the metabolic syndrome. Clin Biochem 48 495–502 2015.

  • Steiner G Schwartz L Shumak S Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 75 124–130 1987.

  • Tettey P Simpson S Jr Taylor B Blizzard L Ponsonby AL Dwyer T Kostner K van der Mei I. An adverse lipid profile is associated with disability and progression in disability in people with MS. Mult Scler 20 1737–1744 2014.

  • Torres A Askari AD Malemud CJ. Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med 3 239–252 2009.

  • Versini M Jeandel PY Rosenthal E Shoenfeld Y. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev 13 981–1000 2014.

  • Weinstock-Guttman B Zivadinov R Mahfooz N Carl E Drake A Schneider J Teter B Hussein S Mehta B Weiskopf M Durfee J Bergsland N Ramanathan M. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 8 127 2011.

  • Wens I Dalgas U Stenager E Eijnde BO. Risk factors related to cardiovascular diseases and the metabolic syndrome in multiple sclerosis – a systematic review. Mult Scler 19 1556–1564 2013.

Journal information
Impact Factor

CiteScore 2018: 1.27

SCImago Journal Rank (SJR) 2018: 0.411
Source Normalized Impact per Paper (SNIP) 2018: 0.441

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 370 322 28
PDF Downloads 284 238 18